A key property needed for the effectiveness of CELMoD drugs, a type of protein degrader, has been discovered.
Scripps Research Institute scientists have discovered a crucial feature that is necessary for CELMoDs, a promising new class of cancer drugs, to work effectively.
CELMoDs are a new class of cancer drugs that function by binding to cereblon, a regulatory protein, which causes the degradation of proteins that drive cancer. Researchers found that for CELMoDs to work effectively, they must cause a specific shape change in cereblon upon binding. This discovery, recently published in the journal Science, allows for the reliable design of effective CELMoDs.
“There are a lot of research groups that have spent considerable time making drugs that bind very tightly to cereblon, but have then scratched their heads in puzzlement that these drugs fail to work,” says study senior author Gabriel Lander, Ph.D., professor in the Department of Integrative Structural and Computational Biology at Scripps Research.
Cereblon works as part of a major protein-disposal system in cells. This system tags targeted proteins with molecules called ubiquitin, which mark the proteins for destruction by roving protein-breaking complexes known as proteasomes. The ubiquitin-proteasome system is used not only to destroy abnormal or damaged proteins, but also to help regulate the levels of some normal proteins. Cereblon is one of the hundreds of “adaptors” used by the ubiquitin-proteasome system to guide the ubiquitin-tagging process toward specific sets of target proteins.
Scientists now recognize that some cancer drugs, including the best-selling myeloma drug lenalidomide (Revlimid), happen to work by binding to cereblon. They do so in a way that forces the ubiquitin-tagging, and consequent destruction, of key proteins that promote cell division—proteins that couldn’t be targeted easily with traditional drugs. Inspired in part by that recognition, drug companies have begun developing cereblon-binding drugs—CELMoDs, also called protein-degradation drugs—that will work even better against myeloma and other cancers.
One enduring problem for the field has been the fact that some of these drugs bind tightly to cereblon, yet fail to cause sufficient degradation of their protein targets. Understanding why this happens has been difficult. Scientists have wanted to use high-resolution imaging methods to map cereblon’s atomic structure and study its dynamics when bound by CELMoDs. But cereblon is a relatively fragile protein that has been hard to capture with such imaging methods.
In the study, Watson spent more than a year devising a recipe for stabilizing cereblon in association with a ubiquitin-system partner protein, in order to image it with low-temperature electron microscopy (cryo-EM). In this way, he was able ultimately to resolve the cereblon structure at a near-atomic scale. Watson also imaged the cereblon-partner complex with CELMoD compounds and target proteins.
The structural data revealed that CELMoDs must bind to cereblon in a way that changes its shape, or conformation. Cereblon, the researchers determined, has a default “open” conformation, but must be switched to a particular “closed” conformation for the ubiquitin-tagging of target proteins.
The main significance of the finding is that drug companies developing CELMoDs now have a much better idea of what their candidate drugs must do to be effective.
“Companies have been developing cereblon-binding protein-degradation drugs that they can see are better degraders, but they didn’t know this was because the drugs are better at driving this closed conformation,” Watson says. “So now they know, and they can test their drugs for this key property.”
Watson’s breakthrough recipe for stabilizing cereblon in preparation for cryo-EM imaging also is now being adopted widely by researchers in this field.
Lander says his lab hopes now to facilitate the development of protein-degradation drugs that work by binding to other ubiquitin-proteasome adaptor proteins besides cereblon. As he notes, the big attraction of the protein-degradation drug strategy is that it can be used to hit virtually any disease-relevant protein, including the very large class of proteins that can’t be targeted with traditional drugs.

News
New material discovery could revolutionize roll-out of global vaccinations
New raw vaccine materials that could make vaccines more accessible, sustainable, and ethical have been discovered. The results of the research have been published in Polymers. Adjuvants are vaccine ingredients that boost a person's immune response [...]
Scientists Develop Incredibly Lightweight Material 4 Times Stronger Than Steel
Researchers developed a light yet strong material by combining two unexpected ingredients—DNA and glass. Working at the nanoscale provides scientists with a deep understanding and precision in crafting and analyzing materials. In broader-scale production, and even [...]
New Implant Doctors Hope Will Cut Cancer Deaths in Half
Researchers at Houston's Rice University are developing an implant that could diminish deaths caused by cancer by half. The device will contain synthetically nurtured human cells and be embedded with sensors to keep track of cancer [...]
Machine learning helps predict drugs’ favorite subcellular haunts
Most drugs are small molecules that bind firmly to a specific target—some molecule in human cells that is involved in a disease—in order to work. For example, a cancer drug's target might be a [...]
Nanotechnology Breakthrough Could Help Treat Blindness
Scientists utilize nanotechnology to address a prevalent cause of vision loss. Scientists have discovered a way to use nanotechnology to create a 3D ‘scaffold’ to grow cells from the retina. This breakthrough could lead [...]
Decoding Women’s Health: Artificial Intelligence Revolutionizes PCOS Diagnosis
NIH study reviews 25 years of data and finds AI/ML can detect common hormone disorder. Artificial intelligence (AI) and machine learning (ML) can effectively detect and diagnose Polycystic Ovary Syndrome (PCOS), which is the most common [...]
Surprising Discovery Could Explain How Coronaviruses Jump Species
New insights are enhancing scientists’ efforts to stay ahead of COVID-19 and the next pandemic. Unexpected new insights into the ways COVID-19 infects cells could shed light on the virus’s adept ability to jump from one species to another [...]
A blood test for long Covid is possible, a study suggests
Scientists can now show key differences in the blood of those who recover from Covid — and those who don't. More than three years into the pandemic, the millions of people who have suffered [...]
FedEx for your cells: this biological delivery service could treat disease
Researchers want to know why cells produce tiny packages called vesicles — and whether these bundles could be used for therapy. Graça Raposo was a young postdoc in the Netherlands in 1996 when she [...]
New study on the genetic magnetization of living bacteria shows great potential for biomedicine
Magnetic bacteria possess extraordinary capabilities due to the magnetic nanoparticles, the magnetosomes, which are concatenated inside their cells. A research team at the University of Bayreuth has now transferred all of the approximately 30 [...]
Ultrathin Nanotech Promises to Help Tackle Antibiotic Resistance
Researchers have invented a nano-thin superbug-slaying material that could one day be integrated into wound dressings and implants to prevent or heal bacterial infections. The innovation – which has undergone advanced pre-clinical trials – [...]
Researchers Discover New Mnemomic Networks in the Brain
The medial temporal lobe (MTL) houses the human memory system. Broadly, it contains the hippocampus, parahippocampal cortex, perirhinal cortex, and entorhinal cortex. “One big challenge in studying the MTL is its great anatomical variability [...]
The Surprising Origin of a Deadly Hospital Infection
C. diff might not originate from external transmission but rather from within the infected patient themselves. Hospital staff dedicate significant effort to safeguard patients from infections during their hospital stay. Through practices ranging from [...]
Google AI breakthrough – huge step in finding genes that cause diseases
Google says it has made a significant step in identifying disease-causing genes, which could help spot rare genetic disorders. A new model named AlphaMissense is able to confidently classify 89 per cent of all [...]
New Study: Everyday Pleasures Can Boost Cognitive Performance
MINDWATCH study reveals cognitive peaks with everyday pleasures. Listening to music and drinking coffee are the sorts of everyday pleasures that can impact a person’s brain activity in ways that improve cognitive performance, including [...]
Moderna reveals new highly targeted COVID-19 vaccine mRNA-1283
Moderna has developed a new and improved version of its COVID-19 vaccine. The unique formulation (mRNA-1283) reduces the vaccine's content from the full-length SARS-CoV-2 spike protein to a narrowly focused encoding of just two [...]